J&J Discloses New Federal Investigations Into Marketing

Drug Industry Daily
A A
Johnson & Johnson (J&J) is facing two new federal investigations into its marketing practices for a drug and a device, just as it is hammering out a settlement over off-label allegations for its antipsychotic Risperdal.

To View This Article:

Login

Subscribe To Drug Industry Daily